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Abstract
Microcin C analogues were recently envisaged as important compounds for the development of novel antibiotics.
Two issues that may pose problems to these potential antibiotics are possible acquisition of resistance through
acetylation and in vivo instability of the peptide chain. N-methylated aminoacyl sulfamoyladenosines were
synthesized to investigate their potential as aminoacyl tRNA synthetase inhibitors and to establish whether these N-
alkylated analogues would escape the natural inactivation mechanism via acetylation of the alpha amine. It was
shown however, that these compounds are not able to effectively inhibit their respective aminoacyl tRNA synthetase.
In addition, we showed that (D)-aspartyl-sulfamoyladenosine (i.e. with a (D)-configuration for the aspartyl moiety), is
a potent inhibitor of aspartyl tRNA synthetase. However, we also showed that the inhibitory effect of (D)- aspartyl-
sulfamoyladenosine is relatively short-lasting. Microcin C analogues with (D)-amino acids throughout from positions
two to six proved inactive. They were shown to be resistant against metabolism by the different peptidases and
therefore not able to release the active moiety. This observation could not be reversed by incorporation of (L)-amino
acids at position six, showing that none of the available peptidases exhibit endopeptidase activity.
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Introduction
Microcin C (McC) (1a, Figure 1) is a natural compound
produced by Enterobacteriaceae. McC consists of a
heptapeptide that is covalently linked through a
phosphoramidate bond to adenosine, with in addition an
aminopropyl moiety esterified to the phosphoramidate linker. In
Escherichia coli, six genes of a plasmid-based mcc cluster
(consisting of the mccABCDE operon and a separately
transcribed mccF gene) determine the production, maturation,
and secretion of McC, as well as provide self-immunity to the
producing cell. The biosynthesis and the mode of action of
McC have already been reviewed comprehensively elsewhere
[1].
During recent years, the potency of this compound and its
analogues, as well as its unravelled mode of action were firmly
established [1-4]. However, to further pursue McC-like
compounds as potential antibiotics, several concerns rise
regarding i) foreseeable mechanisms of bacterial resistance
and ii) in vivo stability of the peptide moiety.
One of the most obvious ways to adopt resistance comes
from the self-producing cell. Once McC is assembled, it
becomes prone to internal processing by different
oligopeptidases, releasing processed McC, a nonhydrolysable
aspartyl-adenylate analogue (1b) within the producing cell
cytoplasm. Inevitable accumulation of processed McC in the
producing cell should inhibit AspRS and lead to cessation of
translation. However, McC producing cells carrying the entire
mcc cluster continue to grow while producing McC. Indeed, the
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Figure 1.  Structures for Microcin C (a), its metabolized form (1b), the reaction products of McC and its sulfamoylated
analogues after metabolism by MccF (1c and 1d), Pro-SA (1e) which is fully resistant against MccE, RimL and MccF, and
the earlier developed sulfamoylated McC analogue (1f).  
doi: 10.1371/journal.pone.0079234.g001
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product of the mccE gene acetylates processed McC and
converts it into a non-toxic compound [5]. Cells carrying the
mcc operon with inactivated mccE grow slowly and apparently
undergo self-poisoning by the McC they produce [5]. The MccE
acetyltransferase is homologous to bacterial N-terminal
acetyltransferases (NATs) of the Rim family. The E. coli
genome encodes three Rim proteins, RimI, RimJ, and RimL,
which acetylate ribosomal proteins S18, S5, and L12,
respectively. The physiological functions of these NATs, and
the significance of ribosomal proteins acetylation for cell
physiology are not entirely clear. Our unpublished data indicate
that RimL, but not RimI or RimJ, can detoxify processed McC
and various other aminoacyl-nucleotides through acetylation of
the alpha amine (T. Kazakov et al., in preparation) and thus
contributes to the basic level of McC resistance.
The mccF gene codes for a serine protease-like enzyme,
and also provides resistance to both exogenous and
endogenously produced McC. MccF detoxifies both intact and
processed McC by cleaving the amide bond of the acyl
phosphoramidate linkage, yielding product 1c [6]. In addition it
was shown that some aminoacyl sulfamoyladenosine (aaSA)
analogues were likewise cleaved by MccF, releasing
sulfamoyladenylate (1d), which was earlier shown to be a
broad-spectrum antibacterial agent by itself [7]. However, while
MccF can only effectively cleave aspartyl and glutamyl
adenylates, RimL and MccE appear to acetylate and therefore
inactivate a broad spectrum of aminoacyl adenylates with little
specificity with respect to the nature of the aminoacyl moiety.
Both findings suggest that bacterial resistance arising due to
activation of a RimL/MccE type enzyme will be a more
significant problem than resistance due to MccF.
We therefore set out to develop modified McC analogues
that would be more resistant to the intrinsic self-immunity
mechanisms of McC producing cells. To this end, two
approaches were examined for their ability to prevent potential
resistance to aaSAs and other aminoacyl tRNA synthetase
(aaRS) inhibitors (such as isosters) of the aminoacyl-
adenylates caused by acetylases such as MccE and RimL. In
first place, we focused on modifying the aminoacyl moiety so
that it would become resistant to acetylation. Secondly, the use
of (D)-amino acids in aaSAs was explored to examine whether
this would still be recognized by the corresponding aaRS and,
subsequently, whether these could escape inactivation by
MccE/RimL.
It is well known that during evolution, cells developed
specialized mechanisms to prevent the incorporation of (D)-
amino acids in their proteins and ribosomally synthesized
peptides. However, several (L)-aminoacyl-tRNA synthetases
can transfer (D)-amino acids onto tRNA. This mis-esterification
will however be corrected by (D)-aminoacyl-tRNA deacylases
(DTD), which hydrolyze the ester bond [8]. Eukaryotes
generally contain DTD1, while plants have DTD2 homologues
[8]. Some bacteria, including most cyanobacteria lack genes
encoding DTD1 homologues. It has also been reported that the
editing site of ThrRS functions as a deacylase, removing non-
cognate (D)-Thr [9]. In addition, several racemases, or in case
of (D)-Glu a transaminase, can convert (D)-amino acids into
(L)-amino acids. Alternatively, (D)-Ala, which is used for the
formation of peptidoglycan in the bacterial cell wall, is produced
from (L)-Ala by conversion via a racemase [10]. Despite the
action of these corrective mechanisms, significant amounts of
(D)-aminoacylated tRNA have been observed in vitro for (D)-
Trp-tRNATrp, (D)-Asp-tRNAAsp [11], and (D)-Tyr-tRNATyr [12,13].
Beside the resistance problem, from a pharmaceutical
perspective the in vivo stability of the peptide moiety remains a
concern. The introduction of (D)-amino acids in the peptide
chain of McC at other positions than the C-terminal one is
interesting as it has been shown in other cases to increase the
plasma half-life of peptides [14]. Provided the bacterial cells
can still release the active principle (via metabolism of the
uptake promoting peptide sequence), this increase in plasma
half-life would render the McC analogues much more
interesting from a therapeutic perspective. Therefore, several
analogues were created with (D)-amino acids to test this
hypothesis and to establish to what extent the intracellular
aminopeptidases can process peptides containing different
combinations of (D)- and (L)- amino acids.
Results
Design
5’-O-[N-[(L)-prolyl]-sulfamoyl]adenosine (Pro-SA, 1e) is not a
substrate for either MccF or MccE [15]. Therefore, a McC
analogue with proline at position seven would seem desirable,
as it will overcome both resistance mechanisms. However,
such compounds could not be synthesized, due to instability of
these derivatives upon deprotection of the intermediates. This
problem was also encountered earlier by Van de Vijver et al.
[16], when studying dipeptidyl-sulfamoyladenosines containing
proline at the C-terminal position.
Nevertheless, the fact that Pro-SA (1e) was not inactivated
by MccE, suggests that the presence of a secondary amine is
sufficient to circumvent acetylation by this enzyme. Hence, we
hypothesized that N-methylated aaSAs could also be resistant
against acetylation by MccE. In contrast, the alpha amine of an
amino acid usually serves as a hydrogen bond donor during
esterification to the cognate tRNA as discussed by Nakama et
al.[17] and as can be shown in many different structures (e.g.
for AlaRS, a class II structure (Min Guo et al., [18]). We
hypothesized however, that following N-methylation, this
moiety still can be protonated and will be able to take part in
ionic interactions or serve as a hydrogen bond donor.
Examination of the E.coli AlaRS structures from Paul
Schimmel's group (see previous ref: Min Guo et al.[18]) shows
that the amine of all three co-crystallized ligands Gly-SA, Ala-
SA and Ser-SA is forming only one hydrogen bond with
Asp235 in the active site cavity. These authors studied the
mistranslation of serine for alanine and also reported the amino
acid binding pocket to be adjustable to different ligands. Visual
inspection of the model already suggests that a single methyl
group on the alpha amine could be easily accommodated. This
is shown in Figure S1 for AlaRS with the modeled sarcosine
analogue 3 sitting in the active site.
To further assess this idea, both 5’-O-[N-[(L)-N-methyl-
leucyl]-sulfamoyl]adenosine (2) and sarcosyl-
sulfamoyladenosine (3) (i.e. 5’-O-[N-[N-methyl-glycyl]-
N-Alkylated Aminoacyl Sulfamoyladenosines
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sulfamoyl]adenosine) (Figure 2) were synthesized and tested
for their inhibitory properties. Compound 2 was selected for its
straightforward synthesis, while compound 3 was selected for
its rather small size, as we hypothesized that the latter might
be active against either GlyRS and/or AlaRS (for all synthetic
discussions we refer to the supplementary pages and the
synthetic schemes (Figures S3 and S4)).
McC analogues comprising (D)-amino acids (Figure 2) were
likewise synthesized to investigate if they would retain
biological activity and at the same time would be resistant
against the action of MccE and/or MccF. Hereto, McC
analogues containing (D)-amino acids in the peptide tail (4-7)
or as the C-terminal amino acid (8) were prepared. Compounds
4-8 were created to investigate the ability i) of cellular
peptidases to process peptide bonds containing (D)-amino
acids and ii) of the YejABEF transporter to recognize and
facilitate entry of McC-like compounds with (D)-amino acids. In
addition, we wanted to investigate whether compounds 8 and 9
((D)-D-SA) would still inhibit the aminoacylation reaction and
would have the potential to escape hydrolysis/acetylation by
MccF and MccE respectively.
Biological Activity
The growth inhibitory properties for all new compounds were
determined by measuring the optical density reached by
cultures of McC-sensitive E. coli in wells of microtiter plates in
the presence of various concentrations of the respective
inhibitors. As shown earlier, the intracellular target of McC
analogs is determined by the C-terminal amino acid, which
remains attached onto the sulfamoyladenosine following
intracellular metabolism [19]. To facilitate activity evaluation
and the mechanism of action studies of newly synthesized
compounds, an E. coli tester strain Ara-Yej (BW39758) was
used, where the yejABEF operon is under control of the
arabinose-inducible araBAD promoter. In the presence of L-
arabinose, higher amounts of Yej-transporters are displayed at
the inner-membrane, making cells more sensitive to McC and
related compounds [2]. In addition to the Ara-Yej strain, E. coli
lacking rim genes (and therefore hypersensitive to McC) was
used as a tester strain. The N-methylated aaSAs (2 and 3)
proved however inactive in whole-cell activity assays with all
cells tested (data not shown). In in vitro aminoacylation
experiments, compound 3 was tested for its potential to inhibit
ProRS, GlyRS and AlaRS and compound 2 was tested for its
ability to inhibit LeuRS in a wild-type cell extract. Established
inhibitors of these enzymes are the respective 5’-O-[N-[L-
aminoacyl]-sulfamoyl]adenosines: Pro-SA, Gly-SA, Ala-SA and
Leu-SA [2-4]. These compounds were therefore used as
positive controls. Unfortunately, no activities comparable to the
positive controls were observed at concentrations of 50 µM
with either compound to either aaRS (Figure 3).
Of the newly synthesized McC analogues (4-8), only
compound 8 showed significant activity in whole-cell activity
screenings against Ara-Yej strain (Figure 4). The effect was
more apparent upon the addition of arabinose to the growth
medium (Figure 4, upper panel), indicating that the YejABEF
transporter is involved in the intake. To confirm the Trojan
horse mode of action, McC-resistant cells in which either an yej
gene, or genes coding for peptidases A, B, and N had been
disrupted were screened for activity with compound 1f serving
as a positive control. Both cells proved fully resistant to
compound 8 (and to compound 1f).
To further corroborate these results and to explain the
absence of biological activity, in vitro studies were performed to
test the ability of all compounds to inhibit tRNA aminoacylation
in cell extracts prepared either from McC hypersensitive E. coli
ΔrimL cells or from McC-resistant ΔpepABN cells. From Figure
5 it can be observed in agreement with the whole cell activity
data, that only compound 8 behaved as tRNA aminoacylation
inhibitor in extracts lacking Rim proteins, but had no effect in
extracts lacking N-peptidases, confirming the requirement for at
least one of these peptidases to release the active moiety.
Since none of the McC analogues containing (D)-amino acids
at positions two to six showed clear inhibition of AspRS or
IleRS in extracts lacking RimL, relative to compounds 9 and 10
which do not require metabolism, we conclude that the
presence of a (D)-amino acid within the McC peptide interferes
with processing.
Figure 2.  Structures for the N-methylated leucyl- (2) and glycyl-sulfamoyladenosine (3), the McC analogues containing (D)-
amino acids (4-8), and the (D)-aspartyl- (9) and (L)-aspartyl-sulfamoyladenosine.  (10).
doi: 10.1371/journal.pone.0079234.g002
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Figure 3.  Lack of aminoacylation inhibition in presence of N-methylated leucyl- (2) and glycyl-sulfamoyladenosine (3) as
potential inhibitors.  Established aminoacyl-sulfamoyl-adenosines (Leu-SA, Gly-SA, Ala-SA and Pro-SA), that were previously
shown to be potent inhibitors of their respective aaRSs, were used as positive controls. All experiments were performed in triplicate.
doi: 10.1371/journal.pone.0079234.g003
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To investigate whether compound 8 would be more resistant
than compound 1f to MccF-catalyzed hydrolysis and/or MccE/
RimL-catalyzed acetylation, and to investigate a possible role
of DTD, a time-course of tRNAAsp aminoacylation inhibition was
followed in two different cell extracts, one prepared from cells
lacking Rim proteins, and another from cells lacking DTD. From
Figure 5 (lower panel) it can be observed that at time point
zero, i.e., immediately after addition of the compounds, there
was no inhibition since the compounds were still
unmetabolized. However, following a time lapse sufficient for
complete processing of wild-type McC, almost full inhibition of
the AspRS-catalyzed reaction was observed with both
compounds. Upon further incubation, the reaction recovered
from inhibition for both compounds. For compound 8 this effect
was more pronounced than for compound 1f, especially in cell
extracts prepared from cells lacking DTD proteins. Using the
Figure 4.  Inhibition profiles of the different McC analogues against (L)-arabinose induced Ara-Yej cells (upper panel) and
against uninduced Ara-Yej cells, respectively.  All experiments were performed in triplicate.
doi: 10.1371/journal.pone.0079234.g004
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Figure 5.  Aminoacylation experiments of the McC analogues containing (D)-amino acids at 50 µM.  Upper panel: 30 min
incubation with a cell extract deficient of RimL.
Middle panel: 30 min incubation with a cell extract deficient of PepA, PepB and PepN.
Lower panel: Comparison of two McC analogues targeting AspRS, compound 8 having a C-terminal D-configuration, compound 1f
having a C-terminal (L)-configuration. Incubation was done with two different cell extracts, lacking either DTD or RimL.
doi: 10.1371/journal.pone.0079234.g005
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latter cell extracts, after 60 min, esterification of Asp-C14 to
tRNAAsp was reduced only 44% (compared to 89% inhibition or
only 11% incorporation at 15 min). In case RimL was absent,
both compounds largely remained inhibitory.
Compound 8 could still reach full activity, comparable to that
of the (L)-D-SA analogue, in extracts prepared from cells
lacking DTD, suggesting that both (D)-D-SA and (L)-D-SA are
equally inhibitory to AspRS and therefore (D)-D-SA does not
need to be isomerised by DTD to inhibit AspRS. This is in
agreement with the observation of Soutourina et al. [11], that
deacylases hydrolyze the ester bond of aminoacylated tRNA,
rather than preventing esterification of (D)-amino acids to
tRNA. One may also notice in Figure 5 (lower panel) that
compound 8 suffers more from inactivation than compound 1f
in RimL deficient extracts.
Compound 8 also showed whole cell activity against (L)-
arabinose induced Ara-Yej cells, albeit to a lower extent than
its (L)-analogue (Figure 4). None of the compounds 8 or 1f
showed activity against Δyej or ΔpepABN cells (data not
shown), confirming their Trojan horse mode of action.
Discussion
From the in vitro aminoacylation experiments with
compounds 2 and 3 it can be concluded that these compounds
lack inhibitory activity against their hypothesized targets (Figure
3). Although with proline, ProRS allows for a secondary amine
within the binding site of the enzyme, Sar-SA (3) is not
tolerated and does not show any major inhibitory binding
affinity for this enzyme. In addition, GlyRS and AlaRS could not
be targeted with this compound, showing that, although Sar-SA
does not have a side chain like Gly-SA, this compound cannot
establish sufficient binding within the active site of these
enzymes. It thus can be concluded that the N-methyl group
prevents inhibitory activity against GlyRS and AlaRS. Likewise,
N-methylated Leu-SA (2) was found to be inactive against
LeuRS. Again, it must be concluded that the Nα-methyl group
in this compound also prevents inhibitory activity. This then
suggests that the Nα-amine is an important recognition point
inside the active site of the enzyme which cannot be modified.
The recent results of Cusack et al. [20] published in the course
of our work, and in which the aminoacylation and proofreading
cycle of bacterial leucyl-tRNA synthetase was highlighted seem
to sustain the latter hypothesis. In their crystal structure of the
E. coli LeuRS in complex with the leucyl-adenylate analogue
Leu-SA, the α-amine of the latter is hydrogen bonded to both
the CO main chain of Leu41 and provides an ionic bond to the
Asp80 side chain. N-methylation therefore not necessarily will
prevent one of these H-bonds as the amine still can be
protonated, but methylation is prohibited as it most probably
would introduce unavoidable clashes (see supplementary
pages and Figure S2 for further comments). In addition, since
Sar-SA was not able to inhibit the aminoacylation reaction as
catalyzed by ProRS it can be concluded that having a
secondary alpha amine is not sufficient for recognition by
ProRS, but that the five membered cyclic amine or at least a
larger structure then the N-methylated glycine is required for
recognition.
Compound 4 did not show whole cell activity either, and was
also shown incapable of inhibiting AspRS in vitro. Since, the N-
terminal amino acid is N-formyl-(L)-methionine, whereas amino
acids at positions two to six are (D)-amino acids, it must be
concluded that the peptidases are not capable of hydrolyzing
(D)-amino acids and can therefore not liberate the active
moiety. This is a somewhat expected result as it has frequently
been shown that the introduction of (D)-amino acids can
prevent the hydrolysis by peptidases [21].
Compounds 5-7 were especially designed to circumvent this
problem; all three compounds contain L-amino acids at the
sixth and seventh position, allowing endopeptidases to cleave
between these two L-amino acids, resulting in release of the
active moiety. Despite this modification, no activity could be
observed. Also the modification in compound 6, inspired by
albomycin whereby pepN hydrolyzes the peptide bond between
a serine and a modified amino acid carrying an acidic side
chain [22], could not rescue the activity. From the in vitro
aminoacylation experiments it can also be concluded that lack
of whole cell activity is due to inability of the peptidases to
metabolize peptides containing (D)-amino acids. Hence, this
shows that the peptidases PepA, PepB and PepN, commonly
known to be responsible for processing of McC and its
analogues [23], only can cleave these compounds as
exopeptidases (i.e. sequentially) and are not able to release
the active moiety via endopeptidic cleavage (i.e. convergently).
Whether or not incorporation of (D)-amino acids in the transport
peptide part interferes with uptake of the McC derivatives by
the YejABEF transporter is less relevant here, as in vitro tests
already show lack of activity. Additional reduced uptake of the
analogues 4-7 however cannot be excluded.
The observation that (D)-D-SA (9) and its McC derivative 8
can inhibit AspRS, shows that the peptidases can metabolize
peptide bonds between two amino acids, whereby the C-
terminal amino acid has the (D)-configuration (as in this case a
(D)-Asp). This suggests that the peptidases involved in this
reaction are only stereoselective for the N-terminal amino acid.
Since it was already frequently observed that (D)-Asp can be
esterified to tRNA, the finding that (D)-D-SA (9) can also inhibit
AspRS can be considered being an expected result. This also
shows that the absolute configuration of the amino acid is not
required for recognition inside the active site of AspRS, and
most probably the same holds for other aaRSs. This finding
matches with the results of Thompson et al. [24] who
concluded that there is only limited chiral specificity for L-Asp,
leading to an esterification of (D)-Asp to tRNAAsp with a rate of
1:4000 for (D)-Asp vs (L)-Asp.
These results are conflicting however with the views of Banik
and Nandi [25-27] who studied the chiral discrimination by
enzymes in protein synthesis via semi-empirical calculation
methods. From their [24]theoretical studies they concluded that
the network of electrostatic interactions between the incoming
amino acid, ATP and the synthetase are highly unfavorable for
incorporation of a (D)-amino acid. Not only in the
aminoacylation step (relevant for our studies), but likewise in
the peptide bond formation reactions, it would be virtually
impossible to incorporate (D)-amino acids in protein structures.
Our results however clearly demonstrate the in vitro inhibitory
N-Alkylated Aminoacyl Sulfamoyladenosines
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effects and hence recognition of our (D)-amino acid containing
aminoacyl adenylate analogues.
Compared to compound 1f, compound 8, was more sensitive
to inactivation by a mechanism that was not solely related to
RimL. This can probably be ascribed to the intrinsic capacity of
AspRS, favouring (L)-Asp over (D)-Asp. It is however unlikely
that the editing site of AspRS is involved in this mechanism as
it has often been shown to hydrolyze only non-cognate amino
acids from tRNA. The inactivation of (D)-D-SA is also reflected
in a lower whole cell activity for this compound, compared to its
(L)-analogue (1f) (Figure 5).
Four important observations were made in this study. First,
we showed that Nα-methylation of Gly-SA and Leu-SA does
not result in inhibition of the respective aaRSs and is therefore
most probably not well tolerated in other aaRSs as well. N-
methylation can therefore also not be considered as a
preventive step against acetylases inactivating most aaSAs.
Secondly, we showed that when one or more of the amino
acids at positions two to six have a (D)-configuration,
metabolism by the peptidases is abolished, thus preventing
release of the active moiety and inhibition of the respective
aaRS. In addition, it was shown that the peptidases primarily
function as exopeptidases, as we did not observe significant
inhibition of AspRS or IleRS with McC analogues containing an
(L)-amino acid at the pre-C-terminal (or sixth) position. Third, if
the C-terminal aspartic acid has a (D)-configuration and amino
acids at positions one to six are in (L)-configuration, the active
moiety was released, resulting in inhibition of AspRS. This
shows that metabolism is independent of the C-terminal amino
acid and only depends on the configuration of the N-terminal
amino acid. Fourth, we have shown that (D)-D-SA is perfectly
capable of inhibiting AspRS. However, this proved a relatively
short lasting inhibition as over time the compound is inactivated
by (predominantly) RimL. A less surprising finding, and
therefore of lesser importance, is that DTD is not involved in
the inhibitory activity of (D)-D-SA.
Materials and Methods
All synthetic procedures, materials used and analysis of the
synthesized compounds can be found in the supplementary
pages.
Whole Cell Activity Determinations
The respective bacteria were grown overnight in Luria Broth
(LB) medium and cultured again the following day in fresh LB
medium or LB-medium containing 5 mM (L)-arabinose.
Compounds were titrated in a 96-well plate using either LB-
medium +/- 5 mM (L)-arabinose to dilute the compounds. To
each well, 85 µL LB-medium +/- 5 mM (L)-arabinose was
added to a total volume of 90 µL. Next, 10 µL of bacterial cell
culture grown to an OD600 of 0.1 was added. The cultures
were next placed into a Tecan Infinite M200® incubator and
shaken at 37 °C, subsequently the OD600 was determined
after 8 h. All experiments have been performed in triplicate.
Bacterial strains used for the evaluations: E. coli Ara-Yej
(BW39758), expressing the yejABEF transporter upon (L)-
arabinose induction; E. coli K-12 (BW28357), used as the wild
type control; E. coli ΔyejA, lacking subunit A of the YejABEF
transporter; and E.coli ΔABN, lacking all three peptidases
pepA, pepB and pepN. ; E. coli Δdtd, lacking (D)-aminoacyl-
tRNA deacylase
Aminoacylation experiments
To assess the degree of inhibition of the aminoacylation
reaction, in vitro tests were performed using the relevant S30
cell extracts.
Preparation of S30 cell extracts.  Cells were grown in 50
mL LB-medium. After centrifuging at 3000 × g for 10 min. the
supernatant was discarded and the pellet was resuspended in
40 mL buffer containing: Tris.HCl or Hepes.KOH (pH = 8.0) (20
mM), MgCl2 (10 mM), KCl (100 mM). The cell-suspension was
centrifuged again at 4800 rpm. This procedure was repeated 2
times. The pellet was resuspended in 1 mL of the following
buffer Tris.HCl or Hepes.KOH (pH = 8.0) (20 mM), MgCl2 (10
mM), KCl (100 mM), DTT (1 mM) and kept at 0 °C.
Subsequently, the cells were sonicated for 10 sec. and left at 0
°C for 10 min. This procedure was repeated for 5-8 times. The
lysate was centrifuged at 15000 g for 30 min at +4 °C.
tRNA aminoacylation reaction.  1 μL of solution containing
inhibitor, 3 μL of E. coli S30 extracts was added. Next, 16 μL of
the following aminoacylation mixture was added: Tris.HCl
(30mM, pH 8.0), DTT (1 mM), bulk of E. coli tRNA (5 g/l), ATP
(3 mM), KCl (30 mM), MgCl2 (8 mM), and the specified, radio
labeled amino acid (40 μM). The reaction products were
precipitated in cold 10% TCA on Whatman 3MM papers, 5 min.
after the aminoacylation mixture was added. The
aminoacylation reaction was carried out at room temperature.
Depending on whether or not processing was needed, variable
time intervals were included between the addition of the cell-
extract and the addition of the aminoacylation mixture. After
thorough washing with cold 10% TCA, the papers were washed
twice with acetone and dried on a heating plate. Following the
addition of scintillation liquid, the amount of radioactivity was
determined in a scintillation counter.
Supporting Information
Figure S1.  AlaRS starting structure from 3hxu.pdb with
sarcosine substituting for alanine in the acive site.
(TIFF)
Figure S2.  LeuRS starting structure from 4aq71.pdb with a
modelled N-methylleucine derivative in the acive site. Top:
introducing the additional methyl moiety on the inhibitor
(magenta) gives clashes with the nucleotide 76b (shown in
green). ionic/H-bond distances are indicated to asp80, to leu41
and to nucleotide 76b.O2'. Bottom: the tRNA is removed from
the model and CA-CB torsion angle of asp80 is adjusted
slightly to accommodate the methyl moiety without clashes.
(TIFF)
Figure S3.  Synthetic scheme for synthesis of the
protected N-methylated buiding blocks. Upper part:
Synthesis of N-methylated and succinimide activated Boc-Leu-
N-Alkylated Aminoacyl Sulfamoyladenosines
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OH. i) NaH, MeI in THF, 0 °C, 30 min. ii) EDCI.HCl, HOSu,
DIPEA in DMF, rt, 16 h. Lower part: Synthesis of Cbz-protected
and succinimide activated sarcosine. i) benzyloxycarbonyloxyl
succinimide, NaHCO3 in H2O/dioxane, 0°C to rt, 7 h. ii) HOSu
and EDCI.HCl in DMF, rt, 16 h.
(TIFF)
Figure S4.  General scheme affording the various McC
analogues. i) N-α-CBZ-(L)-aminoacyl-(tBu or Boc)-
succinimide, DBU in DMF, 6h, rt. ii) for R2 = Z-group, H2, Pd/C
in MeOH, 3h, rt. iii) for R2 = Boc-group, TFA/H2O (5:2), 4h, 0 °C
to rt. iv) Et3N.3HF in THF, 16h, rt. v) the respective protected
peptide (1eq.), HOBt (4 eq.), DIC (4eq.) and DIEA (2 eq.) in
DMF, 16h, rt. vi) TFA/thioanisole/H2O (90/2.5/7.5), 2h, rt.
(TIFF)
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